These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up. Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062 [TBL] [Abstract][Full Text] [Related]
11. FDA notifications. New dosing option approved for Viracept. AIDS Alert; 2003 Jul; 18(7):90. PubMed ID: 12846198 [No Abstract] [Full Text] [Related]
12. FDA approves nelfinavir. Food and Drug Administration. GMHC Treat Issues; 1997 Mar; 11(3):8. PubMed ID: 11364277 [TBL] [Abstract][Full Text] [Related]
13. Fortovase approved: new saquinavir formulation. James JS AIDS Treat News; 1997 Nov; (No 283):1. PubMed ID: 11364907 [TBL] [Abstract][Full Text] [Related]
14. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients. Justesen US; Hansen IM; Andersen AB; Klitgaard NA; Black FT; Gerstoft J; Mathiesen LR; Pedersen C HIV Med; 2005 Sep; 6(5):334-40. PubMed ID: 16156881 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Gatti G; Castelli-Gattinara G; Cruciani M; Bernardi S; De Pascalis CR; Pontali E; Papa L; Miletich F; Bassetti D Clin Infect Dis; 2003 Jun; 36(11):1476-82. PubMed ID: 12766843 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference. Prescott LM Body Posit; 1998 Dec; 11(12):11-2. PubMed ID: 11366134 [TBL] [Abstract][Full Text] [Related]
17. Crixivan warning: keep to three times a day. Gilden D GMHC Treat Issues; 1998 Sep; 12(9):2. PubMed ID: 11365805 [TBL] [Abstract][Full Text] [Related]
18. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Gartland M; Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417 [TBL] [Abstract][Full Text] [Related]
19. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023 [TBL] [Abstract][Full Text] [Related]
20. New protease inhibitor available through expanded access. Posit Aware; 1996; 7(6):7. PubMed ID: 11363981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]